Display options
Cite
Toricelli M, Melo FHM, Hunger A, et al. Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma. Cancers (Basel). 2017;9(4)doi: 10.3390/cancers9040037.
Toricelli, M., Melo, F. H. M., Hunger, A., Zanatta, D., Strauss, B. E., & Jasiulionis, M. G. (2017). Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma. Cancers, 9(4), . https://doi.org/10.3390/cancers9040037
Toricelli, Mariana, et al. "Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma." Cancers vol. 9,4 (2017). doi: https://doi.org/10.3390/cancers9040037
Toricelli M, Melo FHM, Hunger A, Zanatta D, Strauss BE, Jasiulionis MG. Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma. Cancers (Basel). 2017 Apr 21;9(4). doi: 10.3390/cancers9040037. PMID: 28430130; PMCID: PMC5406712.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2017 Apr 21;9(4). doi: 10.3390/cancers9040037.

Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma.

Cancers

Mariana Toricelli, Fabiana H M Melo, Aline Hunger, Daniela Zanatta, Bryan E Strauss, Miriam G Jasiulionis

Affiliations

  1. Pharmacology Department, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil. [email protected].
  2. Pharmacology Department, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil. [email protected].
  3. Center for Translational Investigation in Oncology/LIM 24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, São Paulo 01246-000, Brazil. [email protected].
  4. Center for Translational Investigation in Oncology/LIM 24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, São Paulo 01246-000, Brazil. [email protected].
  5. Center for Translational Investigation in Oncology/LIM 24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, São Paulo 01246-000, Brazil. [email protected].
  6. Pharmacology Department, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil. [email protected].

PMID: 28430130 PMCID: PMC5406712 DOI: 10.3390/cancers9040037

Abstract

High TIMP1 expression is associated with poor prognosis in melanoma, where it can bind to CD63 and β1 integrin, inducing PI3-kinase pathway and cell survival. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), generated under phosphatidylinositol-3-kinase (PI3K) activation, enables the recruitment and activation of protein kinase B (PKB/AKT) and phosphoinositide-dependent kinase 1 (PDK1) at the membrane, resulting in the phosphorylation of a host of other proteins. Using a melanoma progression model, we evaluated the impact of Timp1 and AKT silencing, as well as PI3K, PDK1, and protein kinase C (PKC) inhibitors on aggressiveness characteristics. Timp1 downregulation resulted in decreased

Keywords: PDK1; PI3K pathway; PKC; Timp1; anoikis resistance; melanoma

References

  1. Tumour Biol. 2013 Dec;34(6):3839-51 - PubMed
  2. Nat Rev Cancer. 2017 Jan;17 (1):38-53 - PubMed
  3. J Exp Clin Cancer Res. 2016 Sep 20;35(1):148 - PubMed
  4. Oncotarget. 2016 Jun 7;7(23):33542-56 - PubMed
  5. PLoS One. 2009;4(4):e5120 - PubMed
  6. Nature. 2006 May 25;441(7092):424-30 - PubMed
  7. Immunology. 2015 Dec;146(4):508-22 - PubMed
  8. Sci Signal. 2008 Jul 08;1(27):re6 - PubMed
  9. Semin Cell Dev Biol. 2004 Apr;15(2):161-70 - PubMed
  10. Int J Cancer. 1987 Mar 15;39(3):414-8 - PubMed
  11. Cancer Manag Res. 2013 Aug 23;5:271-80 - PubMed
  12. Mol Cancer Res. 2017 Feb 9;: - PubMed
  13. PLoS One. 2014 Mar 14;9(3):e91656 - PubMed
  14. Am J Cancer Res. 2015 Apr 15;5(5):1649-64 - PubMed
  15. Cancer Res. 2004 Oct 1;64(19):7002-10 - PubMed
  16. Cancer Cell. 2009 Jul 7;16(1):21-32 - PubMed
  17. Mol Cancer. 2013 Mar 25;12:22 - PubMed
  18. Pigment Cell Melanoma Res. 2012 Jul;25(4):466-76 - PubMed
  19. Cancer Res. 2002 Jun 15;62(12):3538-43 - PubMed
  20. J Cell Sci. 2011 Jun 1;124(Pt 11):1819-30 - PubMed
  21. Nat Rev Mol Cell Biol. 2010 Jan;11(1):9-22 - PubMed
  22. Lancet Oncol. 2017 Apr;18(4):435-445 - PubMed
  23. Curr Opin Cell Biol. 2009 Apr;21(2):256-61 - PubMed
  24. J Biol Chem. 2010 Jan 8;285(2):903-13 - PubMed
  25. Front Oncol. 2015 Aug 10;5:183 - PubMed
  26. Transl Oncol. 2009 Dec;2(4):329-40 - PubMed
  27. Neoplasia. 2006 Mar;8(3):231-41 - PubMed
  28. Mol Cell. 2008 Apr 25;30(2):203-13 - PubMed
  29. Cancer Treat Res. 2016;167:17-49 - PubMed
  30. Mol Cancer Res. 2014 Sep;12 (9):1324-33 - PubMed
  31. Curr Med Chem. 2011;18(18):2763-9 - PubMed
  32. Mol Cancer. 2016 Apr 30;15(1):30 - PubMed
  33. Biochem J. 2009 Jan 1;417(1):e5-7 - PubMed
  34. Curr Biol. 1997 Apr 1;7(4):261-9 - PubMed
  35. Oncotarget. 2015 May 20;6(14):12061-79 - PubMed
  36. Oncogene. 2016 Jun 23;35(25):3314-23 - PubMed
  37. Oncogene. 2014 Aug 21;33(34):4330-9 - PubMed
  38. Cancer Res. 2015 Apr 1;75(7):1399-412 - PubMed
  39. Mol Cell Biol. 2014 Feb;34(4):574-94 - PubMed

Publication Types